Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype

P D Leclercq, L S Murray, C Smith, D I Graham, J A R Nicoll, S M Gentleman

Objective: In view of the association of the apolipoprotein E (APOE) ε4 allele with poor outcome after traumatic brain injury we determined the frequency of cerebral amyloid angiopathy (CAA) and the extent of haemorrhagic pathology in relation to APOE genotype in an autopsy series of 88 head injured cases.

Methods: Tissue sections from the frontal and temporal lobes were immunostained for amyloid-β peptide (Aβ) and stained for Congo red to identify vascular amyloid pathology. A semiquantitative assessment of contusions, the total contusion index, was used to estimate the severity of the haemorrhagic pathology. APOE genotypes were determined by polymerase chain reaction of genomic DNA extracted from paraffin embedded tissue sections.

Results: CAA was present in 7/40 (18%) ε4 carriers compared with 1/48 (2%) non-ε4 carriers (p = 0.021, 95% confidence interval [CI] for difference in proportions with CAA 3% to 29%) with 6/40 (4 with CAA) ε4 carriers being homozygotes. Thus the risk of having CAA for ε4 carriers was 8.4 times that for the non-ε4 carriers. However, there was no clear tendency for patients with CAA to have more severe or more numerous contusions (median contusion index 19 (CAA) v 14.5, p = 0.23, 95% CI for difference in medians 5 to 14).

Conclusions: Presence of CAA in head injured cases was significantly associated with possession of an APOE ε4 allele but not with the severity of contusions.

METHODS

Case material

Formalin-fixed paraffin embedded brain tissue and associated clinical information for 88 cases of traumatic head injury were obtained from the archive of the Department of Neuropathology, Institute of Neurological Sciences, Glasgow. All work carried out with this tissue was approved by the ethics committee of the Southern General Hospital. For each case, paraffin sections were selected from both the frontal and medial temporal lobes. The immunohistochemistry was assessed blind to clinical details, pathological features, and APOE genotypes.

Determination of APOE genotypes

The APOE genotypes of the cases were already available from a previous study and had been determined by amplifying genomic DNA extracted from formalin-fixed tissue using a published method.

Immunohistochemistry

Paraffin sections were pretreated in 80% formic acid solution for eight minutes and incubated overnight at 4°C with an antiserum raised against residues 18–22 of the human form of Aβ (clone 1E8, 1:2000 dilution; Glaxo SmithKline, UK). Aβ immunoreactivity was detected using the avidin biotin peroxidase method (ABC Elite kit, Vectors Laboratories, UK) and dianinobenzidine (DAB) as the chromogen. Sections were counterstained with Meyer’s haematoxylin. The alkaline

Abbreviations: APOE, apolipoprotein E; CAA, cerebral amyloid angiopathy; Aβ, amyloid β-protein
method of Congo red was also used to stain amyloid and birefringence was visualised under polarised light.

**Total contusion index**
The contusion index is a measure based on the product of the extent (rated 1–3) and depth (rated 1–4) of contusions in any particular region of the brain. Therefore, a higher numerical index indicates more severe damage. The assessment is carried out both macroscopically and microscopically because there is usually an area of non-haemorrhagic necrosis deep to the haemorrhage, which cannot be assessed macroscopically. By combining the contusion indices from different areas of the same brain it is possible to calculate a total contusion index for that brain.

**Statistical analysis**
Median values between two groups were compared using the Mann–Whitney test and confidence intervals (CI) and among three groups using the Kruskal–Wallis test. Proportions were compared using Fisher’s exact test. Confidence intervals for differences in proportions were calculated using a normal approximation although it is acknowledged that this may be inaccurate for small samples.

**RESULTS**
The head injury cohort consisted of 65 males and 23 females with a median age of 29.5 years ranging from less than a year old to 79 years of age. The median survival time was 46.5 hours and ranged from four hours to 24 days.

**Prevalence of CAA in traumatic brain injury**
Vascular amyloid deposition, identified by Congo red staining and Aβ immunoreactivity, was present in 8/88 (9%) trauma cases examined. All eight cases displayed Aβ and AβVascular amyloid deposition, identified by Congo red staining

**APOE genotypes of head injured patients with CAA**
Six of the 88 trauma cases were APOE ε4 homozygotes, which corresponds to about 7% of the cohort. This was slightly higher than expected but the APOE ε4 allele is known to be associated with poor outcome following traumatic brain injury, including mortality. The APOE ε4 allele frequency was higher in the patients with CAA (11/16; 69%) than in those without (35/160; 22%), and half of patients with CAA (4/8) were APOE ε4 homozygotes compared with 2% (2/80) of those without CAA. Nearly all of the patients with CAA were APOE ε4 carriers (7/8; 88%) compared with 33/80 (41%) patients without CAA (table 1). The degree of Aβ accumulation in the media and adventitia was also more pronounced in ε4 homozygotes (fig 1E–H) than in ε4 heterozygotes.

**APOE ε4 carriers compared with non-ε4 carriers**
A total of 14.5 for the patients without CAA (p = 0.23, 95% CI for difference in medians −5 to 14). Detailed examination of the slides revealed no obvious pattern of anatomical association between the contusions and blood vessels displaying CAA.

**Relation between APOE genotype and contusion index**
The total contusion index values were plotted in relation to APOE genotype in a dose specific manner (fig 3). Again the
data were positively skewed. Non-APOE e4 carriers (n = 48) and APOE e4 heterozygous cases (n = 34) had similar median total contusion index values (14.5 and 12, respectively). APOE e4 homozygotes (n = 6) had a median total contusion index of 25, approximately double that of the other two groups; however, the small number of homozygotes was such that the difference between the medians of the three groups was not statistically significant (p = 0.057).

**DISCUSSION**

The results of the present study show that CAA is present in a relatively small proportion (9%) of patients who have had a fatal head injury. It tended to be present in older patients (median age 58 years; range 21–75), which is consistent with the known association between CAA and ageing. Among head injured patients, CAA was considerably more likely to occur in those with a genetic predisposition conferred by possession of an APOE e4 allele. Again this is consistent with previous studies, which have shown a strong association between CAA and APOE e4. Of particular interest is the possibility that the presence of CAA in patients who experience a head injury may influence the clinical outcome. For example, blood vessels laden with amyloid may be more prone to rupture after trauma, resulting in haemorrhage.

As this was a post-mortem study the only clinical outcome measure available was the survival time of the patients. The head injured cases with CAA had shorter survival time (median 25.5 hours; range 4 hours to 10 days) than trauma cases without CAA (median 48 hours; range 4 hours to 24 days) maybe indicating worse outcome, but because of the small number of cases and wide range in survival time this was not statistically significant.

In this study, the median total contusion index in the APOE e4 homozygous head injured cases was approximately double that of the non-APOE e4 carriers and the heterozygotes although the small number of homozygotes meant that this was not statistically significant. There was no obvious association between the presence of CAA and the severity or extent of contusions, although again the number of cases with CAA was relatively small.

Clinical studies of survivors of head injury have shown that intracranial haematomas in carriers of APOE e4 have significantly larger volume than in non-carriers of APOE e4. In addition a study of pathological features of traumatic brain injury in relation to APOE genotype found a significant association between possession of APOE e4 and severe contusional and severe hypoxic brain damage, but not other forms of pathology. There is also evidence that differences in coagulation profile may contribute to the relationship between APOE e4 and haemorrhage. It is possible that rigid, amyloid-laden blood vessels may be less haemodynamically reactive, perhaps impairing reactive changes in vascular tone and increasing vulnerability to ischaemia. These observations relating to pathological mechanisms seem likely to have clinical relevance because outcome studies indicate that head injured patients who are APOE e4 carriers tend to fare worse than non-carriers of APOE e4 and are also more prone to post-traumatic seizures.

Possession of APOE e2 appears to protect against Alzheimer’s disease in which Aβ deposition is a major pathological feature, both in plaques and in the cerebral vasculature. Remarkably, patients with APOE e2 who do develop CAA seem to be particularly prone to spontaneous haemorrhages perhaps because of susceptibility to the development of CAA-associated vasculopathy.

In the present study, in keeping with these observations, none of the cases with CAA were APOE e2 carriers.

An alternative interpretation of our results revolves around CAA being a consequence of the trauma, particularly in the younger cases and in cases of dementia pugilistica perhaps reflecting deposition along perivascular drainage pathways as a result of increased Aβ in the brain. Weller et al have proposed that the impairment of the periarterial fluid drainage pathway may be responsible for the development of CAA in Alzheimer’s disease and in older people as it may reflect the failure to eliminate Aβ. Other hypotheses revolve around conditions that favour Aβ fibrillogenesis (for example hypoxia, acidosis, altered proteolytic environment, impaired axonal transport) and the ability of smooth muscle cells to clear Aβ. Animal models of CAA have provided a

| Table 1 Clinical detail of cases with and without cerebral amyloid angiopathy (CAA) |
|----------------------------------|----------------|----------------|
| **Median (range) age in years**  | 58 (21–75)     | 26.5 (0–79)    |
| **Cause of injury (n [%])**      |                |                |
| Assault                         | 0 (0)          | 6 (8)          |
| Road traffic accident           | 4 (50)         | 29 (36)        |
| Assault                         | 4 (50)         | 45 (56)        |
| **Median (range) survival time in hours** | 25.5 (16–240) | 48 (4–574)    |
| **Median (range) contusion index** | 19 (0–54)     | 14.5 (0–46)    |
| **APOE genotype (n [%])**       |                |                |
| E2,2                            | 0 (0)          | 2 (2)          |
| E2,3                            | 0 (0)          | 7 (9)          |
| E2,4                            | 0 (0)          | 3 (2)          |
| E3,2                            | 1 (12)         | 27 (34)        |
| E3,3                            | 3 (38)         | 38 (48)        |
| E3,4                            | 3 (38)         | 27 (34)        |
| E4,4                            | 4 (50)         | 40 (52)        |
| APOE allele frequency (n/N [%])  |                |                |
| e2                              | 0 (0)          | 15/160 (9)     |
| e3                              | 5/16 (31)      | 110/160 (69)   |
| e4                              | 11/16 (69)     | 35/160 (22)    |

![Figure 2](http://jnnp.bmj.com/)  
**Figure 2** Dotplot (with x-axis random jitter to distinguish data points) and boxplot (showing the minimum, lower quartile, median, upper quartile and maximum values) of the total contusion index for those without and with cerebral amyloid angiopathy (CAA).

![Figure 3](http://jnnp.bmj.com/)  
**Figure 3** Dotplot (with x-axis random jitter to distinguish data points) and boxplot (showing the minimum, lower quartile, median, upper quartile and maximum values) of the total contusion index for those with 0, 1, and 2 copies of the APOE e4 allele.
different perspective and also raise the possibility that CAA may occur as a consequence of head injury. Increased expression of cytokines is a feature of the response to head injury and increased expression of transforming growth factor (TGF)-β in transgenic mice results in the development of CAA. In addition, focal lesioning of the basal nucleus of Meynert in rabbits, the source of the cholinergic innervation of the cerebral cortex and vasculature, results in the formation of CAA accompanied by parenchymal plaques, within a few days. It is therefore of relevance that in humans the basal nucleus of Meynert is particularly susceptible to damage in severe head injury, particularly in the presence of raised intracranial pressure, brain swelling, and internal herniations resulting in a variety of haemorhagic, ischaemic, and mechanical disturbances. There is evidence that the basal nucleus of Meynert, specifically, may be severely damaged in fatal head injury. 

In conclusion, CAA occurs in a small proportion of head injured patients, predominantly in APOE ε4 carriers. Although the CAA is likely to have been pre-existing in some of the older patients, the presence of leptomeningeal CAA in a 21 year old patient supports the concept that this pathology may have arisen de novo as a consequence of the trauma. However, although it seems there may be an association between APOE ε4 homozygosity and the severity of contuitional damage, it remains unclear whether the CAA provides an anatomical substrate for the poor clinical outcome seen in these patients.

Authors’ affiliations
P D Leclercq, S M Gentleman, Division of Neuroscience and Psychological Medicine, Faculty of Medicine, Imperial College London, London, UK
L S Murray, D I Graham, University Academic Unit of Neuropathology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
C Smith, Neuropathology Lab., Department of Pathology, University of Edinburgh, Western General Hospital, Edinburgh, UK
J A R Nicoll, Clinical Neurosciences, University of Southampton, Southampton General Hospital, Southampton, UK

This study was funded in part by grants from the Medical Research Council (G9814486) and National Institute of Health (AG12411).

Competing interests: JARN and DIG are named applicants on the following patent: Method of prognostic chronic neurodegenerative pathology following a head injury. UK patent application 9415073.7 filed jointly by SmithKline Beecham and University of Glasgow on 27 July 1994; PCT worldwide application PCT/EP95/02827 filed on 13 July 1995; awarded 5 May 1998 (US5747260).

REFERENCES
Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking authors:
- Child health: nocturnal enuresis
- Eye disorders: bacterial conjunctivitis
- Male health: prostate cancer (metastatic)
- Women’s health: pre-menstrual syndrome; pyelonephritis in non-pregnant women

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:
- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with Clinical Evidence editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every six months using any new, sound evidence that becomes available.
- To expand the topic to include a new question about once every 12–18 months.

If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicalevidence.com or contact Klara Brunnhuber (kbrunnhuber@bmjgroup.com).
Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype
P D Leclercq, L S Murray, C Smith, D I Graham, J A R Nicoll and S M Gentleman

*J Neurol Neurosurg Psychiatry* 2005 76: 229-233
doi: 10.1136/jnnp.2003.025528

Updated information and services can be found at:
http://jnnp.bmj.com/content/76/2/229

*These include:*

**References**
This article cites 47 articles, 17 of which you can access for free at:
http://jnnp.bmj.com/content/76/2/229#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Injury (469)
- Trauma (470)
- Neurological injury (384)
- Trauma CNS / PNS (384)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/